Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Woyach · SciRah

Researcher profile · Semantic Scholar

J. Woyach

Share profile

J. Woyach — researcher profile on SciRah

h-index: 60
Works: 511
Citations: 17K

Most-cited papers

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024.
W. Wierda, Jennifer R. Brown, J. S. Abramson, Farrukh T. Awan +32 more
2024The Journal of the National Comprehensive Cancer Network60 citations Open access
Semantic Scholar
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
Jeff P. Sharman, M. Egyed, W. Jurczak, A. Skarbnik +23 more
2025Blood55 citations Open access
Semantic Scholar
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib
J. Woyach, Dan Jones, W. Jurczak, T. Robak +14 more
2024Blood49 citations Open access
Semantic Scholar
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study
A. Kittai, D. Bond, Ying Huang, S. Bhat +29 more
2024Journal of Clinical Oncology43 citations
Semantic Scholar
Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.
J. Woyach, Gabriela E. Perez Burbano, A. Ruppert, Cecelia R. Miller +28 more
2024Blood42 citations Open access
Semantic Scholar
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
W. Wierda, N. Shah, Che-Ah Y. Chan, David Lewis +31 more
2024The Lancet Haematology33 citations
Semantic Scholar
International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC Recommendations.
A. Kittai, M. Marchetti, O. Al-Sawaf, O. Benjamini +25 more
2025Blood27 citations Open access
Semantic Scholar
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice
P. Blombery, T. Chatzikonstantinou, Marina Gerousi, R. Rosenquist +13 more
2025Leukemia27 citations Open access
Semantic Scholar
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
N. Shah, Michael Wang, L. Roeker, Krish Patel +31 more
2024Haematologica25 citations Open access
Semantic Scholar
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia
P. Hampel, M. Swaminathan, K. Rogers, E. Parry +12 more
2024Blood Advances19 citations Open access
Semantic Scholar
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials
M. Davids, J. Sharman, P. Ghia, J. Woyach +8 more
2024Blood Advances19 citations Open access
Semantic Scholar
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
A. Kittai, Ying Huang, Sarah Miller, John N. Allan +41 more
2025Blood Cancer Journal17 citations Open access
Semantic Scholar
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
J. Woyach, L. Qiu, S. Grosicki, T. Wrobel +24 more
2025Journal of Clinical Oncology17 citations Open access
Semantic Scholar
A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies
M. Tees, D. Bond, Nadia Khan, Farrukh T. Awan +5 more
2024Blood14 citations
Semantic Scholar
Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia.
John T Patton, J. Woyach
2024Seminars in hematology (Print)14 citations
Semantic Scholar
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling
Alexander R. Marr, Madeline Halpin, Dominique L. Corbin, Yerdanos Asemelash +18 more
2024Experimental Hematology & Oncology13 citations Open access
Semantic Scholar
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia
J. Ravikrishnan, D. Diaz-Rohena, Elizabeth M Muhowski, Xiao-Kui Mo +27 more
2024Haematologica11 citations
Semantic Scholar
CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL.
M. Shadman, A. Kater, J. Woyach, Jian-Yong Li +5 more
2024Journal of Clinical Oncology10 citations Open access
Semantic Scholar
Determining the relationship of p16INK4a and additional molecular markers of aging with clinical frailty in hematologic malignancy
A. Rosko, Mohamed I. Elsaid, J. Woyach, Nowshin Islam +6 more
2024Journal of cancer survivorship10 citations
Semantic Scholar
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown, Bastien Nguyen, S. Desikan, Helen Won +23 more
2025Blood9 citations Open access
Semantic Scholar
Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL
Q. Han, Yan Gu, Huimin Xiang, Linyao Zhang +10 more
2024Blood9 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.
W. Wierda, Jennifer R. Brown, Jeremy S. Abramson, Farrukh T. Awan +33 more
2026The Journal of the National Comprehensive Cancer Network8 citations
Semantic Scholar
Predictive Ability of Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Calculator in Hematologic Malignancy
A. Rosko, Ying Huang, Sarah A Wall, Alice Mims +10 more
2024Journal of Geriatric Oncology8 citations Open access
Semantic Scholar
Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study
Che-Ah Y. Chan, M. Patel, T. Eyre, W. Jurczak +35 more
2025Blood7 citations
Semantic Scholar
Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study
Michael Wang, Jonathon B. Cohen, Nirav Shah, W. Jurczak +33 more
2025Blood6 citations
Semantic Scholar
Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotypes and phenotypes in chronic lymphocytic leukemia
Gage S. Black, Xiao-Meng Huang, Yi Qiao, Philip J. Moos +4 more
2025Genome Research6 citations Open access
Semantic Scholar
Covalent Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Aseel Alsouqi, J. Woyach
2024Clinical Lymphoma, Myeloma & Leukemia6 citations
Semantic Scholar
Clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy in patients with chronic lymphocytic leukemia on behalf of the American Society for Transplantation and Cellular Therapy.
M. Kharfan-Dabaja, Ambuj Kumar, Javier Pinilla-Ibarz, Jennifer R. Brown +17 more
2025Transplantation and Cellular Therapy5 citations Open access
Semantic Scholar
Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
Meghan C. Thompson, S. Bhat, W. Jurczak, K. Patel +18 more
2024Blood5 citations
Semantic Scholar
CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL
P. Patten, A. Kater, J. Woyach, Jian-Yong Li +5 more
2024Blood5 citations
Semantic Scholar
Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies
S. Vasu, Evandro D. Bezerra, N. Denlinger, Nicole Szuminski +17 more
2024Blood4 citations
Semantic Scholar
IBCL-147 AC676, an Orally Bioavailable BTK Chimeric Degrader in Patients With B-cell Malignancies
Manish Patel, Michael Tees, Nadia Khan, Farrukh T. Awan +5 more
2024Clinical Lymphoma, Myeloma & Leukemia4 citations
Semantic Scholar
Abstract PO-009: AC676 a BTK Chimeric Degrader: Phase 1 study in patients with B-cell Malignancies
M. Patel, M. Tees, Farrukh T. Awan, N. Khan +4 more
2024Blood Cancer Discovery4 citations
Semantic Scholar
When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia
Samon Benrashid, J. Woyach
2026Current Hematologic Malignancy Reports3 citations Open access
Semantic Scholar
Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor
J. Woyach, Danielle B. Brander, Bo-Yu Hu, Kerry Rogers +9 more
2025Blood3 citations
Semantic Scholar
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study
A. Visentin, E. Gaffo, M. Fürstenau, Kerry A. Rogers +44 more
2025Leukemia3 citations Open access
Semantic Scholar
Frontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton's Tyrosine Kinase Inhibitors: A Comprehensive Overview.
S. Bhat, J. Woyach
2025Hematology/Oncology Clinics of North America3 citations
Semantic Scholar
A Bayesian framework to study tumor subclone–specific expression by combining bulk DNA and single-cell RNA sequencing data
Yi Qiao, Xiao-Meng Huang, Philip J. Moos, Jonathan M. Ahmann +6 more
2024Genome Research3 citations Open access
Semantic Scholar
Mutations in the Bruton Tyrosine Kinase (BTK) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)
A. Skarbnik, Alexey V. Danilov, Marc S. Hoffmann, Farrukh T. Awan +10 more
2024Blood3 citations
Semantic Scholar
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study
Krish Patel, J. Vose, Sunita D. Nasta, Jennifer R. Brown +27 more
2026Blood Advances2 citations Open access
Semantic Scholar
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.
M. Palomba, Manish Patel, T. Eyre, Wojciech Jurczak +35 more
2026The Lancet Haematology2 citations
Semantic Scholar
Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib
Britten K. Gordon, Lillian M Cool, Elizabeth M Muhowski, Lianbo Yu +28 more
2025Blood2 citations
Semantic Scholar
Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
J. Woyach, L. Qiu, S. Grosicki, Tomasz Wróbel +22 more
2025Blood2 citations
Semantic Scholar
PKCβ inhibitor MS-553 displays preclinical efficacy in both treatment-naïve and BTK inhibitor-resistant Chronic Lymphocytic Leukemia.
Britten K. Gordon, Elizabeth M Muhowski, Jyotsana Singh, J. Ravikrishnan +28 more
2025Blood Cancer Discovery2 citations
Semantic Scholar
Precursor Hematologic Conditions: Diagnosis, Risk Stratification, Clinical Implications, and Management.
Yuxin Liu, P. Desai, Omar Nadeem, J. Woyach +1 more
2025American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2 citations Open access
Semantic Scholar
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis
Catherine C Coombs, J. Woyach, Jennifer R. Brown, P. Ghia +18 more
2025Current Medical Research and Opinion2 citations Open access
Semantic Scholar
BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton's Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia
M. Davids, John M. Burke, J. Woyach, M. Shahkarami +8 more
2024Blood2 citations
Semantic Scholar
Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models
Alexander R. Marr, Madeline Halpin, Dominique L. Corbin, Britten K. Gordon +12 more
2024Blood2 citations
Semantic Scholar
Safety of extended pirtobrutinib exposure in relapsed and/or refractory B-cell malignancies
L. Roeker, Catherine C. Coombs, N. Shah, W. Jurczak +17 more
2024Acta Haematologica2 citations Open access
Semantic Scholar
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia
Richard R. Furman, W. Wierda, P. Patten, J. Chaves +14 more
2026Blood Advances1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

W. Wierda×15
Invite
W. Wierda — researcher profile on SciRah
W. Jurczak×13
Invite
W. Jurczak — researcher profile on SciRah
T. Eyre×12
Invite
T. Eyre — researcher profile on SciRah
P. Ghia×11
Invite
P. Ghia — researcher profile on SciRah

×9

Invite

Che-Ah Y. Chan — researcher profile on SciRah

Farrukh T. Awan×8

Invite

Farrukh T. Awan — researcher profile on SciRah

Invite

T. Munir — researcher profile on SciRah

Invite

Shuo Ma — researcher profile on SciRah

Invite

C. Ujjani — researcher profile on SciRah

Catherine C Coombs×7

Invite

Catherine C Coombs — researcher profile on SciRah

Joanna M. Rhodes×7

Invite

Joanna M. Rhodes — researcher profile on SciRah

Donald E. Tsai×7

Invite

Donald E. Tsai — researcher profile on SciRah